Skip to content
SPC Logo

Zopiclone 7.5mg Tablets

Last Updated on eMC 27-Jul-2016 View document  | Kent Pharmaceuticals Ltd Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 27-Jul-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 1 - Name of the medicinal product
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 23-Jun-2016

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

Sections 1, 4.2, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.2, 6.4, 6.5, 6.6 and 10 of the SPC updated in line with the Brand leader SPC Zimovane.

Updated on 28-Jan-2015 and displayed until 27-Jul-2016

Reasons for adding or updating:

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose

Date of revision of text on the SPC: 24-Feb-2014

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:


  • Section 4.2: Treatment duration added for transient insomnia (2-5 days) and short term insomnia (2-3 weeks).
  • Section 4.4: Advice added that benzodiazepines are not indicated to treat patients with severe hepatic insufficiency. Advice added for patients with respiratory insufficiency that a lower dose is recommended. Advice added for use in children that the safe and effective dose of Zopiclone has not been established. Advice added that the elderly should be given a reduced dose. Advice added for patients with depression that zopiclone does not constitute a treatment for depression and may even mask its symptoms. A listing of psychiatric and paradoxical reactions has been added.
  • Section 4.8: Information regarding the undesirable effects of this medicine updated. Advice added on how to report adverse side effects.
  • Section 4.9: Information added to the symptoms and management of overdose

Updated on 16-Jul-2012 and displayed until 28-Jan-2015

Reasons for adding or updating:

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects

Date of revision of text on the SPC: 28-Jun-2012

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

To update sections 4.4, 4.5 and 4.8 of the SPC in line with an RFI which has not yet been fulfilled and the QRD template. Minor typographical errors are also to be amended within section 4.2 and 4.3. As a consequence, the PIL has been updated.

Updated on 13-Apr-2012 and displayed until 16-Jul-2012

Reasons for adding or updating:

  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Legal Category:POM

Black Triangle (CHM): NO

Company contact details

Kent Pharmaceuticals Ltd

Company image
Address

Joshna House, Crowbridge Road, Orbital Park, Ashford, Kent, TN24 0GR

Fax

0845 437 5567

Medical Information e-mail
Telephone

0845 437 5565

Medical Information Direct Line

+44 (0)1233 506 574

Customer Care direct line

0800 220 280

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

zopiclone

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue